Isatuximab-Irfc /ML
Phase 2Small molecule
Isatuximab-Irfc /ML is one of 23 small molecule programs targeting Elderly Patients. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Elderly Patients
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Approved
Rituxan
RochePhase 3
Venclexta
AbbViePhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Cytosar
TevaPhase 2
Polivy
RochePhase 2
Azulfidine
PfizerPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Elderly Patients1 trial
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
Active, not recruiting·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 2·NCT04891809·198 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Isatuximab-Irfc /ML. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details